Conbercept is a promising option for the treatment of wet AMD, according to a systematic review and meta-analysis of randomized controlled trials carried out in China, where the VEGF inhibitor was developed.
China is currently the only country where the treatment is approved.
The literature search included PubMed, Embase, the Cochrane Library, the China National Knowledge Infrastructure (CNKI), the VIP database and Wanfang database. Eighteen RCTs encompassing 1,285 participants, all single-center studies conducted in China, were included in the review. Comparisons were with conservative